Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2016-05-02 Director's Dealing
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2016-05-02 English
OWNERSHIP DOCUMENT
Director's Dealing
2016-05-02 English
OWNERSHIP DOCUMENT
Director's Dealing
2016-05-02 English
OWNERSHIP DOCUMENT
Director's Dealing
2016-05-02 English
PRE 14A 2016
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is titled as a Preliminary Proxy Statement for the 2016 Annual Meeting of Stockholders of Caladrius Biosciences, Inc. The content includes details about the meeting date, location, agenda items such as election of directors, executive compensation advisory vote, reverse stock split proposal, ratification of auditor appointment, and other shareholder meeting logistics. It also includes instructions on voting, proxy solicitation, record date, quorum requirements, and voting rights. This type of document is specifically designed to solicit shareholder votes and provide information necessary for shareholders to make informed voting decisions at the Annual General Meeting. It is not the Annual Report, Earnings Release, or any other financial or regulatory filing. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI). The document length is substantial (15,000 characters), indicating it is the full proxy statement and not just an announcement or notice. Confidence in this classification is very high due to the explicit SEC form type (Schedule 14A) and the detailed proxy-related content.
2016-04-29 English
10-K/A DEC 31 2015
Annual Report FY 2015
2016-04-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.